Puig J - Search Results

1

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.

Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, Ramírez-Morros A, Rodríguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila-Jáuregui M, Torrano-Soler P, San José A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia Garcia V, Vidal-Alaball J, Millan A, Contreras E, Grifols JR, Ancochea À, Galvan-Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farré M, Pradenas E, Blanco J, Àngel Rodriguez-Arias M, Fernández Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitjà O; CONV-ERT Group. Alemany A, et al. Among authors: puig j. Lancet Respir Med. 2022 Mar;10(3):278-288. doi: 10.1016/S2213-2600(21)00545-2. Epub 2022 Feb 9. Lancet Respir Med. 2022. PMID: 35150610 Free PMC article. Clinical Trial.

2

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.

Negredo E, Bonjoch A, Paredes R, Puig J, Clotet B. Negredo E, et al. Among authors: puig j. Clin Infect Dis. 2005 Sep 15;41(6):901-5. doi: 10.1086/432879. Epub 2005 Aug 15. Clin Infect Dis. 2005. PMID: 16107993 Clinical Trial.

3

The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.

Negredo E, Clotet B, Puig J, Pérez-Alvarez N, Ruiz L, Romeu J, Moltó J, Rey-Joly C, Blanco J. Negredo E, et al. Among authors: puig j. AIDS. 2006 Feb 28;20(4):619-21. doi: 10.1097/01.aids.0000210617.90954.0e. AIDS. 2006. PMID: 16470128 Clinical Trial.

4

Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.

Bonjoch A, Negredo E, Puig J, Erkizia I, Puig T, Cabrera C, Ruiz L, Clotet B. Bonjoch A, et al. Among authors: puig t, puig j. AIDS. 2006 Sep 11;20(14):1896-8. doi: 10.1097/01.aids.0000244212.15951.2b. AIDS. 2006. PMID: 16954734 Clinical Trial.

5

Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.

Negredo E, Puigdomènech I, Marfil S, Puig J, Pérez-Alvarez N, Ruiz L, Rey-Joly C, Clotet B, Blanco J. Negredo E, et al. Among authors: puig j. J Antimicrob Chemother. 2008 Feb;61(2):400-4. doi: 10.1093/jac/dkm470. Epub 2007 Dec 14. J Antimicrob Chemother. 2008. PMID: 18083750 Clinical Trial.

6

Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.

Negredo E, Puig J, Aldea D, Medina M, Estany C, Pérez-Alvarez N, Rodríguez-Fumaz C, Muñoz-Moreno JA, Higueras C, Gonzalez-Mestre V, Clotet B. Negredo E, et al. Among authors: puig j. AIDS Res Hum Retroviruses. 2009 Apr;25(4):451-5. doi: 10.1089/aid.2008.0230. AIDS Res Hum Retroviruses. 2009. PMID: 19320569

7

The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.

Buzón MJ, Dalmau J, Puertas MC, Puig J, Clotet B, Martinez-Picado J. Buzón MJ, et al. Among authors: puig j. AIDS. 2010 Jan 2;24(1):17-25. doi: 10.1097/QAD.0b013e328331c81e. AIDS. 2010. PMID: 19770695

8

CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART.

Massanella M, Negredo E, Pérez-Alvarez N, Puig J, Ruiz-Hernández R, Bofill M, Clotet B, Blanco J. Massanella M, et al. Among authors: puig j. AIDS. 2010 Apr 24;24(7):959-68. doi: 10.1097/QAD.0b013e328337b957. AIDS. 2010. PMID: 20177358

9

Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.

Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, Villarroya J, Villarroya F, Moltó J, Santos JR, Clotet B, Blanco J. Negredo E, et al. Among authors: puig j. Clin Infect Dis. 2010 May 1;50(9):1300-8. doi: 10.1086/651689. Clin Infect Dis. 2010. PMID: 20367229

10

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients.

Patricia E, Domingo P, Gutierrez M, Gracia M, Fuster M, Molto J, Puig J, Perez-Alvarez N, Clotet B, Negredo E. Patricia E, et al. Among authors: puig j. Curr HIV Res. 2010 Sep;8(6):467-70. doi: 10.2174/157016210793499358. Curr HIV Res. 2010. PMID: 20636275 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

906 results

Search Page

Filters